Inogatran (H-314-27) is a synthetic thrombin inhibitor primarily used for the prevention of arterial and venous thrombotic disorders; it dose-dependently inhibits thrombus formation, prolongs time to occlusion (TTO), reduces thrombus weight, improves venous caval blood flow, and decreases the overall incidence of thrombotic occlusion in animal models of venous thrombosis.